Rescue Rates for Talimogene laherparepvec Use in Loco-Regionally Progressing Cutaneous Melanoma Refractory to PD1 Inhibition

Am Surg. 2024 Jun;90(6):1809-1812. doi: 10.1177/00031348241241648. Epub 2024 Apr 2.

Authors

Morgan E Roberts¹, Katie Vines¹, Frances G Sullivan², Thuy Phung^{2

3}, Joe S Liles^{1

2}, John H Howard^{1

2}

Affiliations

¹ Department of Surgery, University of South Alabama, Mobile, AL, USA.
² Whiddon School of Medicine, University of South Alabama, Mobile, AL, USA.
³ Department of Pathology, University of South Alabama, Mobile, AL, USA.

PMID: 38562109
DOI: 10.1177/00031348241241648

No abstract available

MeSH terms

Aged
Aged, 80 and over
Antineoplastic Agents, Immunological / therapeutic use
Biological Products / therapeutic use
Female
Herpesvirus 1, Human
Humans
Immune Checkpoint Inhibitors / therapeutic use
Male
Melanoma*
Melanoma, Cutaneous Malignant
Middle Aged
Oncolytic Virotherapy / methods
Retrospective Studies
Skin Neoplasms*